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Cardiovascular diseases (CVD) are responsible for the highest mortality rates globally. About one-third of the 
CVD-related casualties derive from ischemic heart diseases, which cause an irreversible injury to the myo-
cardium. As a result of the very limited capacity of the heart tissue to recover from the ischemic insult, this 
usually leads to remodeling and scarring of the cardiac tissue, eventually progressing to irreversible heart 
failure. Currently, there is no major discovery of an effective cure to restore the function of an injured heart. 
Therefore, there is an unmet need to find a permanent solution for patients suffering from ischemic heart 
disease (IHD) and heart failure. In this regard, nanoparticles made of biomaterials called the attention of the 
scientific community as potential platform to deliver different therapeutics to the injured heart. Particulate 
nanomedicines, currently at the pre-clinical stage, are arising as a promising tool to provide minimally inva-
sive treatment, an important aspect to take into account for clinical translation and patient compliance, and 
specifically deliver therapeutics to the injured myocardium. Here, we discuss about the current knowledge on 
the nanomedicines investigated for myocardial infarction, and how we see they can help and support medi-
cal doctors in shaping the future of IHD treatments. 
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Figure 1. Schematic representation of post-myocardial infarction left ventricular remodeling. The acute 
phase encompasses thinning and elongation of the fibrous scar within the infarcted zone. Subsequent left 
ventricular dilation is caused by diffuse myocyte hypertrophy associated with increased apoptotic cell death 
(not shown) and increase in interstitial collagen. This image was constructed using Medical Servier Art 
(Servier Medical Art, 2019).  
Current therapeutic approaches to treat IHD, and more specifically MI, include secondary prevention 
pharmacological therapy stated above which decreases blood pressure, cardiac overload and risk of 
arrhythmia, as well as invasive procedures for restoration of reperfusion and aid blood systemic distribution 
with pacemaker and ventricular assist devices. These mainly manage the patient’s symptomatology rather 
than restoring cardiac function, decreasing mortality and morbidity, and prevent to some extent the 
development of heart failure (Ibanez et al. 2018). Apart from heart transplantation (with its associated 
complications), despite continuous efforts put in the search for a cure for MI and heart failure, to date this 
has not been found.  
The fundamentals of heart development and MI pathological processes at the cellular and molecular 
levels have been deeply investigated (Xin et al. 2013) in order to develop therapeutic solutions to restore 
cardiac function after MI. Nanotechnology, and the development of nanomedicines for repair/protection/
regeneration of the heart upon an ischemic event, took off only a few decades ago, being at the pre-clinical 
stage of research for therapy of IHD. In fact, according to the European Medicines Agency, nanomedicines 
are designed systems for clinical applications with at least one component at nanoscale size, which renders 
definable specific properties and characteristics to this kind of therapeutic platform. The purposes of 
nanomedicines are to: (1) tackle unmet medical needs (e.g. integrating efficacious molecules that otherwise 
could not be used because of their high toxicity) and by exploiting multiple mechanisms of actions; and (2) 
to maximize efficacy and reduce dose and toxicity, by allowing drug targeting, control the specific drug 
release, improve transport across biological barriers, and regulate preferential distribution within the body 
(e.g. in the ischemic myocardial injury or in cancer lesion areas) (European Medicines Agency, 2019). Such 
therapeutic approach differs from the conventional drug therapy as it allows targeted delivery of therapeutics 
to the tissue of interest (in this case, the ischemic heart). The use of nanoparticles opens up a panoply of 
opportunities for new drug molecules that are very potent but possess poor physicochemical properties such 
as low solubility, easy degradation and enhanced toxicity: engineered nanoparticles protect labile cargos 
from degradation, as well as protecting the body from toxic effects of cargos with narrow therapeutic 
window that otherwise would distribute throughout the entire body.  
It all started with simple liposomes, the most primitive forms of nanomedicines developed primarily 
for cancer, but later applied to MI (Levchenko et al. 2012). As bare nanocarriers are quite unspecific and are 
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Ischemic heart disease (IHD): statistics and facts 
The world has seen tremendous development in the medical field, significantly impacting the health 
of the global society over the past few decades. Recent examples include the Human Genome Project 
(Lander et al. 2001) targeted therapies for cancer (Tran et al. 2017), as well as the development of primary 
preventive (e.g. control and treatment of hypertension, hypercholesterolemia, diabetes, and smoking 
decline), symptom-management therapies (e.g. timely use of thrombolysis therapy and percutaneous 
coronary intervention (PCI)), as well as secondary prevention therapies (statins, beta-blockers, ACE-
inhibitors, angiotensin receptor blockers, aspirin and diuretics) for patients with established cardiovascular 
diseases (CVD) (Reddy et al. 2015, Arnett et al. 2019). Particularly, therapies for ischemic heart disease 
(IHD) have dramatically decreased the world mortality by 40% (Mensah et al. 2017). However, an 
astonishing 17 million people still die of CVD globally, particularly from heart attacks and strokes. This 
accounts to approximately 31% of all deaths worldwide (WHO, 2017). In Europe, the impact of CVD on loss 
of productivity, combined with hospitalization and healthcare costs amounts to a total of €210 billion per 
year (EHN, 2017). 
IHD are the main cause of death among Finns. Although the same trend in decrease of mortality is 
verified in Finland (Salomaa et al. 1996), and men’s and women’s age-standardized mortality has decreased 
by over 40%, IHD still causes one in five deaths in men and one in six deaths in women, with almost 10,000 
casualties reported in 2017 (Official Statistics of Finland, 2017). Due to an aging population and sedentary 
life-style, in addition to the increase in incidence of co-morbidities, such as obesity, hypercholesterolemia, 
diabetes and hypertension, growing incidences of CVD are major drivers for the global myocardial infarction 
(MI) treatment market, expected to reach $1.7 billion by end of 2022 (Zion Market Research, 2017). 
Nanomedicines for cardiovascular diseases 
Myocardial Infarction (MI), commonly known as heart attack and inserted in the category of IHD, 
leads to death of the area of cardiac tissue upon blockage of a coronary artery, ultimately developing to an 
irreversible ischemic cardiomyopathy and heart failure, compromising severely cardiac function (Figure 1). 
Due to the poor turnover of cardiomyocytes and the inability of the heart to recover or regenerate from a 
cardiac insult, it is important to devise novel solutions to tackle the problem of irreversible heart failure.  
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HEART DISEASES AND  
NANOMEDICINES: CURRENT STATE
Ische ic heart disease (IHD): statistics and facts
The world has seen tremendous development in the 
medical field, signific ntly impacting the health of 
the global society over the past few decades. Recent 
examples include the Human Genome Project (Lan-
der et al. 2001) targeted therapies for cancer (Tran et 
al. 2017), as well as the development of primary pre-
ventive (e.g. control and treatment of hypertension, 
hypercholesterolemia, diabetes, and smoking decli-
ne), sympt m-management therapies (e.g. timely use 
of thrombolysis therapy and percutaneous corona-
ry intervention (PCI)), as well s secondary preventi-
on therapies (statins, beta-blockers, ACE-inhibitors, 
angiotensin receptor blockers, aspirin and diuretics) 
for patients with established cardiovascular diseases 
(CVD) (Reddy et al. 2015, Arnett et al. 2019). Parti-
cularly, therapies for ischemic heart disease (IHD) 
have dramatically decreased the world mortality by 
40% (Mensah et al. 2017). However, an astonishing 
17 million people still die of CVD globally, particu-
larly from heart attacks and strokes. This accounts 
to approximately 31% of all deaths worldwide (WHO, 
2017). In Europe, the impact of CVD on loss of pro-
ductivity, combined with hospitalization and health-
care costs amounts to a total of €210 billion per year 
(EHN, 2017).
IHD are the main cause of death among Finns. Al-
though the same trend in decrease of mortality is veri-
fied in Finland (Salomaa et al. 1996), and men’s and 
women’s age-standardized mortality has decreased by 
over 40%, IHD still causes one in five deaths in men 
and one in six deaths in women, with almost 10,000 
casualties repo ted in 2017 (Official Statistics of Fin-
land, 2017). Due to an aging population and sedentary 
life-style, in addition to the increase in incidence of co-
morbidities, such as obesity, hypercholesterolemia, di-
abetes and hypertension, growing incidences of CVD 
are major drivers for the global myocardial infarction 
(MI) treatment market, expected to reach $1.7 billion 
by end of 2022 (Zion Market Research, 2017).
Nanomedicines for cardiovascular diseases
Myocardial Infarction (MI), commonly known as 
heart attack and inserted in the category of IHD, 
leads to death of the area of cardiac tissue upon 
blockage of a coronary artery, ultimately develo-
ping to an irreversible ischemic cardiomyopathy and 
heart failure, compromising severely cardiac functi-
on (Figure 1). Due to the poor turnover of cardio-
myocytes and the inability of the heart to recover or 
regenerate from a cardiac insult, it is important to 
devise novel solutions to tackle the problem of irre-
versible heart failure. 
 Current therapeutic approaches to treat IHD, and 
more specifically MI, include secondary prevention 
pharmacological therapy stated above which decreas-
es blood pressure, cardiac overload and risk of ar-
rhythmia, as well s inv sive procedur s for restora-
tion of reperfusion and aid blood systemic distribu-
tion with pacemaker and ventricular assist devices. 
These mainly manage the patient’s symptomatolo-
gy rather than restoring cardiac function, decreasing 
mortality and morbidity, and prevent to some extent 
the development of heart fa lure (Ibanez et al. 2018). 
Apart from heart transplantation (with its associated 
complications), despite continuous efforts put in the 
search for a cure for MI and heart failure, to date this 
has not been found. 
The fundamentals of heart devel pment and MI 
pathological processes at the cellular and molecular 
levels have been deeply investigated (Xin et al. 2013) in 
order to develop therapeutic solutions to restore car-
diac function after MI. Nanotechnology, and the de-
velopment of nanomedicines for repair/protection/
regeneration of the hea t up n an i c emic event, 
took ff only a few decades ago, bei g at the pre-
clinical stage of research for therapy of IHD. In fact, 
according to the European Medicines Agency, nano-
medicines are designed systems for clinical applica-
tions with at least one component at nanoscale size, 
which renders definable specific properties and char-
acteristics to this kind of therapeutic platform. The 
purposes of nanomedicines are to: (1) tackle unmet 
medical needs, e.g. integrating efficacious molecu-
les that otherwise could not be used because of their 
high toxicity and by exploiting multiple mechanisms 
of action; and (2) to maximize efficacy and reduce 
dose and toxicity, by allowing drug targeting, control 
the specific drug release, improve transport across 
biological barriers, and regulate preferential distri-
bution within the body (e.g., in the ischemic myo-
c rdial injury or in cancer lesion areas) (European 
Medicines Agency, 2019). S ch therapeutic approach 
differs from the conventional drug therapy as it al-
lows targeted delivery of therapeutics to the tissue 
of interest (in this case, the ischemic heart). The use 
of nanoparticles opens up a panoply of opportuni-
ties for new drug molecules that are very potent but 
possess poor physicochemical properties such as low 
solubility, easy degradation and enhanced toxicity: 
engineered nanoparticles protect labile cargos from 
degradation, as well as protecting the body from tox-
ic effects of cargos with narrow thera utic window 
that oth rwise would i ribute throughout the en-
tire body. 
 It all started with simple liposomes, the most 
primitive forms of nanomedicines developed pri-
marily for cancer, but later applied to MI (Levchen-
ko et al. 2012). As bare nanocarriers are quite unspe-
cific and are rapidly captured by the liver and retic-
uloendothelial system for clearance upon systemic 
administration, incorporation of stabilizers like pol-
Figure 1. Schematic representation of post-myocardial infarction left ventricular remodeling. The acute 
phase encompasses thinning and elongation of the fibrous scar within the infarcted zone. Subsequent 
left ventricular dilation is caused by diffuse myocyte hypertrophy associated with increased apoptotic cell 
death (not shown) and increase in interstitial collagen. This image was constructed using Medical Servier 
Art (Servier Medical Art, 2019). 
Figure 2. Nanomedicine-based strategies developed to tackle ischemic cardiomyopathy. (ROS = reactive 
oxygen species). Reprinted with permission from reference (Mahmoudi et al. 2017).
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yethylene glycol (PEG) to increase circulation time, 
and targeting moieties to direct the nanocarriers to-
wards the ischemic cardiac tissue took place as early 
as 1995 (Khaw et al. 1995) in order to deliver more ef-
ficiently therapeutic drugs. From this point onwards, 
several nanomedicines have been developed for tar-
geted drug delivery for therapy of MI, by using the 
most varied (bio)materials and targeting strategies 
(Ferreira et al. 2017, Ferreira et al. 2018). As a fast ad-
vancing field, nanoplatforms have been developed 
with mechanisms of action such that they can: (1) 
target and break down coronary artery plaques and 
prevent injuries caused by stenosis or occlusion of 
arteries – preventive nanomedicines; and (2) reduce 
adverse effects of reperfusion injuries and promote 
cardiac repair/salvage/regeneration after MI, through 
sustained and targeted delivery of cells, biomolecules 
and paracrine factors – therapeutic nanomedicines 
(Figure 2) (Mahmoudi et al. 2017). Our focus in this 
short commentary is mainly on the therapeutic na-
nomedicines for MI.
Different materials and different targeting strat-
egies are employed to achieve a higher nanoparti-
cle accumulation in the heart and higher therapeu-
tic efficacy in different animal models (Ferreira et al. 
2015, Mahmoudi et al. 2017). For example, SOMag5 
magnetic nanoparticles are being used to aid the en-
graftment of embryonic and induced-cardiomyocyte 
cells to ischemic myocardium using a strong magnet-
ic field, improving heart repair processes (Ottersbach 
et al. 2018). Liposomes have been functionalized with 
antibodies targeting the overexpressed angiotensin II 
type 1 receptor in the heart upon MI (Dvir et al. 2011). 
Due to advantages such as high drug encapsulation 
efficiency, polymeric multifunctional poly(glycidal 
methacrylate) nanoparticles were developed for the 
transport of a combination of two therapeutics with 
antioxidant and anti-hypertrophic properties (Har-
dy et al. 2015). To tackle the invasive route of admin-
istration, calcium phosphate nanoparticles of very 
small size (50 nm) were developed for administration 
via inhalation route, for rapid translocation from the 
pulmonary tree to the bloodstream, and direct trans-
port to the myocardium and targeted release of their 
therapeutic cargos (Miragoli et al. 2018). These are 
a few examples of the efforts put to develop nano-
medicines, at the moment in the preclinical stage, to 
improve the quality of life of patients suffering from 
IHD in the future.
In Finland, and particularly at the University of 
Helsinki, such work has also been developed. At the 
group of Nanomedicines and Biomedical Engineer-
ing (www.3iregeneration.com), we have used porous 
silicon (PSi) and spermine-acetalated dextran to for-
mulate nanomedicines for targeted drug delivery for 
therapy and imaging of cardiac ischemic injury, work 
that culminated in a recent Ph.D. thesis (Figure 3) 
(Ferreira, 2017). These materials were chosen due to 
their intrinsic properties, such as biocompatibility, 
biodegradability, customized particle preparation, 
surface functionalization, efficient drug loading and 
encapsulation, and tunable release of the therapeu-
tic cargos. Both PSi and dextran-based nanoparti-
cles were stabilized for higher circulation time in 
the bloodstream, and further decorated with atrial 
natriuretic peptide (ANP) for targeting purposes be-
cause the release of natriuretic peptides and the in-
trinsic increase in expression of their receptors is one 
of the markers for cardiac injury. Both PSi and dex-
tran nanoparticles showed good cytocompatibility in 
cardiac cell cultures and biocompatibility (Tölli et al. 
2014, Ferreira et al. 2016, Ferreira et al. 2017). We have 
also demonstrated specific cardiac cell−nanoparticle 
interactions through natriuretic peptide receptors, 
in the presence of ANP in the nanoparticles’ surface, 
showing the successful development of targeted na-
nomedicines to the heart (Ferreira et al. 2016, Ferrei-
ra et al. 2018). Upon labeling the nanoparticles with 
radioisotope Indium-111, the nanoparticles displayed 
a preferential accumulation and selectivity towards 
the endocardial layer of the ischemic (but not nor-
mal) heart in a rat MI model (Figures 3A and 3B). 
In vivo delivery of a cardioprotective small drug mol-
ecule (Kinnunen et al. 2018) by the developed PSi-na-
noplatform showed attenuation of the extracellular 
signal-regulated kinase pathway that is involved in 
the hypertrophic signaling of the injured heart (Fer-
reira et al. 2017). In addition, the development of bi-
ofunctionalized and dual-loaded dextran-based na-
noparticles for potential application in heart cellular 
reprogramming was proven successful, by utilizing 
acidic pH-triggered drug delivery of the two poorly 
water-soluble cargos. Subsequent treatment of car-
diac non-myocytes showed therapeutic modulation 
of key signaling pathways involved in the direct fibro-
blast reprogramming into cardiomyocytes (Ferreira 
et al. 2018). Thus, the works described here provide 
insights that may be useful for the future develop-
ment of nanomedicines with cardioprotection and 
cardiac regeneration therapeutic purposes for appli-
cation in the clinic.
 
CONCLUSIONS
Overall, although the advancement of nanomedici-
nes field for therapy of IHD is still in the pre-clini-
cal stage, it definitely shows therapeutic potential for 
promoting repair and/or regeneration of the injured 
heart tissue, especially in the acute stage of MI. Ho-
wever, translation to the clinical setting remains elu-
sive, where limitations like the ability to overcome 
biological barriers, time-consuming and complex 
preparation of the nanomedicines, their reproduci-
bility and scalability, are factors that are yet challen-
ging to be addressed in the clinical development and 
commercialization. Furthermore, new cardiac mar-
kers that would allow a more efficient targeting are 
still to be discovered, being that some of the research 
focus in this field is shifting towards other nanopar-
ticle-related therapeutic strategies, such as the uti-
lization of extracellular vesicles, due to their disco-
vered intrinsic cargos and roles in cellular processes 
that possess potential to improve cardiac function 
(Bollini et al. 2018). We believe that with the techno-
logical advancements where novel and more advan-
ced nanomedicines are being developed, there is an 
increased hope that these could be translated to the 
clinic in the near future. As more and more proof-
of-concept nanomedicines emerge for MI therapy, 
new insights on the nanomedicines’ particularities, 
versatility, and advantages offer a wide range of op-
portunities for the development of adaptable tools 
to fight MI and heart failure.
expression of their receptors is one of the markers for cardiac injury. Both PSi and dextran nanoparticles 
showed good cytocompatibility in cardiac cell cultures and biocompatibility (Tölli et al. 2014, Ferreira et al. 
2016, Ferreira et al. 2017). We have also demonstrated specific cardiac cell−nanoparticle interactions 
through natri retic peptide receptors, i  the presence of ANP in the nanoparticles’ surface, showing the 
successful development of targeted nanomedicines to the heart (Ferreira et al. 2016, Ferreira et al. 2018). 
Upon labeling the nanoparticles with radioisotope Indium-111, the nanoparticles displayed a preferential 
accumulation and selectivity towards the endocardial layer of the ischemic (but not normal) heart in a rat MI 
model (Figures 3A and 3B). In vivo delivery of a cardi protective small drug mol cule (Ki nunen et al. 
2018) by the devel ped PSi-nanoplatform showed attenuation of the extracellular si nal-regulated kinase 
pathway that is involved in the hypertrophic signaling of the injured heart (Ferreira et al. 2017). In addition, 
the development of biofunctionalized and dual-loaded dextran-based nanoparticles for potential application 
in heart cellular reprogramming was proven successful, by utilizing acidic pH-triggered drug delivery of the 
two poorly water-soluble cargos. Subsequent treatment of cardi c non-myocytes showed therap utic 
modulation of key signaling pathways involved in the direct fibroblast reprogramming into cardiomyocytes 
(Ferreira et al. 2018). Thus, the works described here provide insights that may be useful for the future 
development of nanomedicines with cardioprotection and cardiac regeneration therapeutic purposes for 
application in the clinic. 
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Figure 3. Targeting strategy with imaging modality of nanomedicines to the MI. (A) Heart-targeted 
nanomedicines in the blood stream (blue triangle), ANP targeting moiety (yellow arrow), stabilizing polymer 
coat (green arrow) and nanocarrier-loaded drug (red arrow). (B) Representative sagittal single-photon 
emission computed tomography (SPECT) images, showing the biodistribution of the nanoparticles at 10 min 
after intravenous administration in a MI rat model. White arrows indicate the location of the heart. 
Undecylenic acid modified thermally hydrocarbonized porous silicon NPs without (Un-P-D) and with (Un-
P-D-ANP) targeting atrial natriuretic peptide. (C) Representative hematoxylin and eosin (H&E) stainings 
and autoradiograms of apical, basal and medial rat heart sections treated with the targeted nanomedicines. 
Red areas demonstrate higher regional nanoparticle accumulation. Reprinted and modified with permission 
from reference (Ferreira et al. 2017). 
Conclusions 
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Figure 3. Targeting strategy with imaging modality of nanomedicines to the MI. (A) Heart-targeted nano-
medicines in the blood stream (blue triangle), ANP targeting moiety (yellow arrow), stabilizing polymer coat 
(green arrow) and nanocarrier-loaded drug (red arrow). (B) Representative sagittal single-photon emission 
computed tomography (SPECT) images, showing the biodistribution of the nanoparticles at 10 min after 
intrave ous administrat on in a MI r t model. White arrows indicate the location f the hear . Undecyle-
nic acid modified thermally hydrocarbonized porous silicon NPs without (Un-P-D) and with (Un-P-D-ANP) 
targeting atrial natriuretic peptide. (C) Representative hematoxylin and eosin (H&E) stainings and auto-
radiograms of apical, basal and medial rat heart sections treated with the targeted nanomedicines. Red 
areas demonstrate higher regional nanoparticle accumulation. Reprinted and modified with permission 
from reference (Fe reira et al. 2017).
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TIIVISTELMÄ
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Sydän- ja verisuonitaudit ovat maailmanlaajuises-
ti kaikkein yleisin kuolinsyy. Noin kolmasosa näis-
tä kuolemantapauksista liittyy iskeemisiin sydän-
sairauksiin, jotka voivat aiheuttaa palautumattomia 
muutoksia sydänlihakseen. Yleensä sydänlihas toi-
puu huonosti iskemiasta ja seurauksena voi olla ar-
pikudoksen muodostuminen ja sydämen vajaatoi-
minnan kehittyminen. Tällä hetkellä ei ole olemas-
sa tehokasta hoitokeinoa vaurioituneen sydämen 
toiminnan palauttamiseksi, minkä vuoksi tällaisille 
korjaaville hoidoille on suuri tarve. Viime vuosikym-
meninä tutkijat ovat kehittäneet erilaisia biomateri-
aaleihin perustuvia nanopartikkeleita lääkeaineiden 
kuljettamiseksi vaurioituneeseen sydämeen. Näitä 
prekliinisissä tutkimuksissa olevia nanokokoisia lää-
kehiukkasia pidetään lupaavina työkaluina. Niiden 
avulla voidaan kohdennetusti kuljettaa lääkeainei-
ta sydänlihakseen käyttäen mahdollisimman vähän 
potilaaseen kajoavia toimenpiteitä, mikä on tärke-
ää hoitomyöntyvyyden kannalta. Tässä tieteellises-
sä kommentissa käydään läpi mikä on tämänhetki-
nen tilanne sydäninfarktin hoitoon tarkoitettujen 
nanolääkkeiden kehittelyssä ja miten tulevaisuudessa 
em. lääkkeet voivat olla hyödyllisiä iskeemisten sy-
dänsairauksien hoidossa. 
Avainsanat: sydänsairaus, sydäninfarkti, nanolääk-
keet, kohdentaminen
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Aiheena lääkkeet ja ympäristö.
 
Keväällä 2020 Dosis-lehden teemana on lääkealan kestävä kehitys. 
Kutsumme nyt tutkijoita terveydenhuollon eri osa-alueilta 
kirjoittamaan kyseiseen teemanumeroon.
 
A tikkelit voivat kä itellä lääkevalmisteisiin ja/tai lääkeaineisiin liittyviä 
kestävän kehityksen haasteita ympäristöriskejä ja ratkaisumalleja 
la jasti eri näkökulmista. Alkuperäistutkimusten lisäksi myös aiheeseen 
liittyvät katsaukset, väitöskirjan tai opinnäytetyön tiivistelmät, tieteelliset 
kommentit, kirjeet ja vastaukset ovat tervetulleita.
Dosis on ainoa suomenkielinen farmasian alan lehti, jossa julkaistaan 
farmasian ja lähialojen tutkimuksia (www.dosis.fi). Dosis julkaistaan 
ilmaisena Open Access -verkkolehtenä, joka tavoittaa kymmeniä 
tuhansia terveydenhuollon ammattilaisia ja juttuihin liitettyjen 
sometyökalujen avulla myös laajemman yleisön.
Toivomme, että innostuit ajatuksesta ja haluat antaa panoksesi 
tähän Dosiksen teemanumeroon ja näin edistää lääkealan kestävään 
kehitykseen liittyvän tutkimustiedon levittämistä terveydenhuollon 
ammattilaisille ja myös valveutuneille kansalaisille.
Ilmoitathan kiinnostuksestasi lokakuun 2019 alkuun mennessä 
Dosiksen sähköpostiosoitteeseen (dosis@farmasialiitto.fi), 
päätoimittaja A neli Ritalalle (anneli.ritala@vtt.fi) tai vieraileville 
toimittajille, Tiina Sikaselle (tiina.sikanen@helsinki.fi) ja 
Jari Yli-Kauhaluomalle (jari.yli-kauhaluoma@helsinki.fi).
www.dosis.fi
Contribute to the 
special issue! 
 
Theme Pharmaceuticals and the Environment.
In spring 2020, Dosis will have a theme issue on sustainable 
pharmacy. We now call upon contributions from researchers 
and professionals across the healthcare sector.
The articles may discuss the sustainability challenges and solutions 
as well as environmental risk assessment of both pharmaceutical 
products and active pharmaceutical ingredients. Besides original 
research papers, also review articles, thesis summaries 
(doctoral dissertations and other graduation works), scientific 
opinion articles, letters and responses are welcomed.
Dosis is the sole Finnish journal in the field of pharmaceutical 
research, publishing contributions associated with pharmacy 
and related disciplines (www.dosis.fi).
Dosis is an Open Access online journal, which reaches tens of thousands 
of healthcare professionals, and more through social media.
We wish you to have got your attention, so you could contribute to 
the theme issue and so enforce the implementation of sustainable 
pharmacy through dissemination of scientific findings among healthcare 
professionals and the environmentally concerned public. 
Please indicate your interest to submit via email latest by the beginning 
of October to one of the following addresses: directly to Dosis  
(dosis@farmasialiitto.fi) or the Editor-in-Chief Anneli Ritala  
(anneli.ritala@vtt.fi), or to the Guest Editors Tiina Sikanen  
(tiina.sikanen@helsinki.fi) and  
Jari Yli-Kauhaluoma (jari.yli-kauhaluoma@helsinki.fi).
www.dosis.fi
